Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Atara Biotherap (NQ: ATRA)
40.80 USD  +0.80 (+2.00%)
Official Closing Price  /  Updated: 4:26 PM EDT, Sep 20, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 279,200
Open 40.10
Bid (Size) 33.00 (1)
Ask (Size) 42.00 (1)
Prev. Close 40.00
Today's Range 39.65 - 41.50
52wk Range 12.65 - 54.45
Shares Outstanding 43,949,486
Dividend Yield N/A
Performance
YTD
+125.41%
+125.41%
1 Month
+10.42%
+10.42%
3 Month
-11.40%
-11.40%
6 Month
+6.11%
+6.11%
1 Year
+161.54%
+161.54%
Top News
More News
Atara Biotherapeutics Appoints Cancer Research and Clinical Development Veteran, Roy Baynes, to its Board of Directors
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today... Read More
from GlobeNewswire News Releases
Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today... Read More
from GlobeNewswire News Releases
More News
Read More
Atara Biotherapeutics to Participate at Two Upcoming Conferences
from GlobeNewswire News Releases
Analysis: Positioning to Benefit within Quanex Building Products, Molecular Templates, Atara Biotherapeutics, Forward Industries, Apollo Endosurgery, and Myomo — Research Highlights Growth, Revenue, a
from GlobeNewswire News Releases
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
from GlobeNewswire News Releases
Atara Biotherapeutics Announces Second Quarter 2018 Financial Results and Recent Operational Progress
from GlobeNewswire News Releases
Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference
from GlobeNewswire News Releases
Atara Biotherapeutics Opens State-of-the-Art Operations and Manufacturing Facility to Support Robust Off-the-Shelf T-Cell Immunotherapy Pipeline
from GlobeNewswire News Releases
Atara Biotherapeutics’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas
from GlobeNewswire News Releases
Atara Biotherapeutics Announces Publication of New Research Linking Epstein-Barr Virus (EBV) Infection and Multiple Sclerosis (MS)
from GlobeNewswire News Releases
Atara Biotherape Falling Today on Above-Average Volume (ATRA)
from Comtex SmarTrend® News Briefs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.